Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NAD alerts FDA, FTC to SlimForce 7 ad

This article was originally published in The Tan Sheet

Executive Summary

After failing to reach Toronto-based SlimForce 7, which markets a weight-loss product as a supplement under the same name, the Council of Better Business Bureaus unit refers the firm to FDA, the Federal Trade Commission and the Competition Bureau of Canada. NAD said Aug. 10 that a magazine ad claims SlimForce 7 "is a treatment aimed at all those who can't lose weight," enables loss of 11 pounds in one week and modifies the body's metabolism. The claims qualify as "too good to be true" under FTC's reference guide for bogus weight-loss claims (1"The Tan Sheet" Dec. 15, 2003). NAD said SlimForce 7 did not respond to multiple communication attempts
Advertisement

Related Content

NAD reviews weight-loss supplement
Slap On The Wrist? FTC Puts Out Media Guidance On Weight Loss Ad Claims
Slap On The Wrist? FTC Puts Out Media Guidance On Weight Loss Ad Claims

Topics

Advertisement
UsernamePublicRestriction

Register

PS103237

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel